2022 Shareholders' Meeting approved the “lifting of non-competition restrictions on newly appointed directors and their representatives”case.

 Synmosa's 2022 Shareholders' Meeting approved the
"lifting of non-competition restrictions on newly
appointed directors and their representatives"case.

1.Date of the shareholders' meeting resolution:2022/05/25
2.Name and title of the managerial officer with permission
 to engage in competitive conduct:
Director-Lin, Chih-Hui
Director-Chiu Hui-Lan
Corporate Director-Representative of FORMOSA TIME PHARMACEUTICAL CO., LTD.:
Zhang, You-Peng
Corporate Director-Representative of FORMOSA TIME PHARMACEUTICAL CO., LTD.:
Huang, Li-Wen
Independent Director-Liu, Xiang-Lang
Independent Director-Lin, Xiu-Mei
Independent Director-Wang Chien-Jen
3.Items of competitive conduct in which the officer is
permitted to engage:
The directors of the company have invested in or operated other companies
with the same business scope as the company
4.Period of permission to engage in the competitive conduct:
Term of office as a director (including independent director) of the
company
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Approved by the chairman after consultation with all shareholders present
and after voting
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):N/A
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company's finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:NONE